ASKA bolsters female health portfolio with ulipristal deal
This article was originally published in Scrip
Executive Summary
HRA Pharma has granted ASKA Pharmaceutical exclusive rights to develop and commercialise ulipristal acetate in Japan, in a deal that builds on ASKA's strong presence in the country's women's and reproductive health sector.